Canaccord Genuity Maintains Buy on Travere Therapeutics, Raises Price Target to $70
Canaccord Genuity analyst Edward Nash maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target from $62 to $70.
Read original at benzingaStocks · News reference
Evercore ISI Group Maintains Outperform on Travere Therapeutics, Raises Price Target to $78
Evercore ISI Group analyst Liisa Bayko maintains Travere Therapeutics (NASDAQ:TVTX) with a Outperform and raises the price target from $68 to $78.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 10, 2026, 4:38 PM
- Checked
- Aug 10, 2026, 4:38 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Wedbush Maintains Outperform on Travere Therapeutics, Raises Price Target to $75
Wedbush analyst Laura Chico maintains Travere Therapeutics (NASDAQ:TVTX) with a Outperform and raises the price target from $61 to $75.
Read original at benzingaTD Cowen Maintains Buy on Travere Therapeutics, Raises Price Target to $75
TD Cowen analyst Tyler Van Buren maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target from $60 to $75.
Read original at benzinga